Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites

Clinical Therapeutics, 2016 04; 38(4): 905-917. e-pub ahead of print 2016/03/08

This review compared the real-world effectiveness of everolimus-based therapy versus endocrine monotherapy or chemotherapy in postmenopausal hormone receptor positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) patients with multiple metastatic sites.

View abstract


Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ